Pfizer Says VYNDAQEL And VYNDAMAX Approved By FDA - Quick Facts

Pfizer Inc. (PFE) announced Monday that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

from RTT - Biotech http://bit.ly/2V35IS4
via IFTTT